Clinical Report: Utilization of the Seraph® 100 Affinity Blood Filter in a Pediatric Case
Overview
This report details the use of the Seraph® 100 Microbind® affinity blood filter in a 7-year-old girl with refractory septic shock due to invasive Streptococcus pyogenes. Following hemoperfusion, the patient showed hemodynamic and metabolic improvement, although she required bilateral lower-limb amputations due to ischemia.
Background
Expand on the mechanisms of septic shock and the role of Streptococcus pyogenes.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
The Seraph® 100 filter was used in a 7-year-old girl with refractory septic shock.
Hemoperfusion was initiated 42 hours after ICU admission, following severe multiorgan dysfunction.
Post-treatment, there was a noted reduction in vasoactive support and improvement in metabolic parameters.
The patient stabilized without requiring extracorporeal membrane oxygenation.
Despite the improvement, the patient experienced severe peripheral ischemia leading to bilateral lower-limb amputations.
Findings suggest a potential role for hemoperfusion as an adjunctive therapy in selected pediatric cases of septic shock.
Clinical Implications
The use of the Seraph® 100 filter may provide a novel adjunctive treatment option for pediatric patients experiencing refractory septic shock. Clinicians should consider this approach in conjunction with standard therapies, particularly in cases where conventional management fails.
Conclusion
This case highlights the potential benefits of pathogen-binding hemoperfusion in pediatric septic shock, although further studies are necessary to establish its safety and efficacy. The findings underscore the need for careful consideration of treatment options in severe cases.
